Transdermal fentanyl in the management of cancer pain in ambulatory patients: An open-label pilot study

Julie E. Hammack, James A. Mailliard, Charles Lawrence Loprinzi, Raylene M. Respond, Judith R. O'Fallon, Mary B. Wilwerding, Nicholas F. Reuter, John C. Michalak, Pat Fidler, Angela W. Miser

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We performed an open label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our 7-day study included 35 patients all of whom had failed a trial of an opioid analgesic conventionally used for moderate pain. Patients received either a 25 μg/hr or 50 μg/hr fentanyl transdermal patch depending on prior opioid dose. Pain was measured daily utilizing visual analogue (VAS) and categorical (CAT) scales. Hours of nighttime sleep, quality of life, toxicities, and use of rescue medication were also assessed. There was a 24%-29% reduction in mean VAS and CAT pain scores as compared with the baseline and a 25% increase in mean hours of nighttime sleep. Fifty-nine percent of those patients responding (46% of all study patients) were satisfied to very satisfied with the analgesia provided by transdermal fentanyl. Six percent of all study patients were not at all satisfied with the pain relief obtained. Toxicities were similar to those seen with other opioids. No patient developed severe sedation or respiratory depression. The 25-50 μg/hr patch appears to be a safe starting dosage in ambulatory patients previously receiving opioids conventionally used for moderate pain.

Original languageEnglish (US)
Pages (from-to)234-240
Number of pages7
JournalJournal of Pain and Symptom Management
Volume12
Issue number4
DOIs
StatePublished - Oct 1996

Fingerprint

Fentanyl
Opioid Analgesics
Pain
Sleep
Transdermal Patch
Cancer Pain
Respiratory Insufficiency
Analgesia
Analgesics
Quality of Life
Population

Keywords

  • cancer pain
  • opioids
  • Transdermal fentanyl

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Transdermal fentanyl in the management of cancer pain in ambulatory patients : An open-label pilot study. / Hammack, Julie E.; Mailliard, James A.; Loprinzi, Charles Lawrence; Respond, Raylene M.; O'Fallon, Judith R.; Wilwerding, Mary B.; Reuter, Nicholas F.; Michalak, John C.; Fidler, Pat; Miser, Angela W.

In: Journal of Pain and Symptom Management, Vol. 12, No. 4, 10.1996, p. 234-240.

Research output: Contribution to journalArticle

Hammack, JE, Mailliard, JA, Loprinzi, CL, Respond, RM, O'Fallon, JR, Wilwerding, MB, Reuter, NF, Michalak, JC, Fidler, P & Miser, AW 1996, 'Transdermal fentanyl in the management of cancer pain in ambulatory patients: An open-label pilot study', Journal of Pain and Symptom Management, vol. 12, no. 4, pp. 234-240. https://doi.org/10.1016/0885-3924(96)00191-1
Hammack, Julie E. ; Mailliard, James A. ; Loprinzi, Charles Lawrence ; Respond, Raylene M. ; O'Fallon, Judith R. ; Wilwerding, Mary B. ; Reuter, Nicholas F. ; Michalak, John C. ; Fidler, Pat ; Miser, Angela W. / Transdermal fentanyl in the management of cancer pain in ambulatory patients : An open-label pilot study. In: Journal of Pain and Symptom Management. 1996 ; Vol. 12, No. 4. pp. 234-240.
@article{d4e2d9fc28e1489e9329a67cc004b26c,
title = "Transdermal fentanyl in the management of cancer pain in ambulatory patients: An open-label pilot study",
abstract = "We performed an open label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our 7-day study included 35 patients all of whom had failed a trial of an opioid analgesic conventionally used for moderate pain. Patients received either a 25 μg/hr or 50 μg/hr fentanyl transdermal patch depending on prior opioid dose. Pain was measured daily utilizing visual analogue (VAS) and categorical (CAT) scales. Hours of nighttime sleep, quality of life, toxicities, and use of rescue medication were also assessed. There was a 24{\%}-29{\%} reduction in mean VAS and CAT pain scores as compared with the baseline and a 25{\%} increase in mean hours of nighttime sleep. Fifty-nine percent of those patients responding (46{\%} of all study patients) were satisfied to very satisfied with the analgesia provided by transdermal fentanyl. Six percent of all study patients were not at all satisfied with the pain relief obtained. Toxicities were similar to those seen with other opioids. No patient developed severe sedation or respiratory depression. The 25-50 μg/hr patch appears to be a safe starting dosage in ambulatory patients previously receiving opioids conventionally used for moderate pain.",
keywords = "cancer pain, opioids, Transdermal fentanyl",
author = "Hammack, {Julie E.} and Mailliard, {James A.} and Loprinzi, {Charles Lawrence} and Respond, {Raylene M.} and O'Fallon, {Judith R.} and Wilwerding, {Mary B.} and Reuter, {Nicholas F.} and Michalak, {John C.} and Pat Fidler and Miser, {Angela W.}",
year = "1996",
month = "10",
doi = "10.1016/0885-3924(96)00191-1",
language = "English (US)",
volume = "12",
pages = "234--240",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Transdermal fentanyl in the management of cancer pain in ambulatory patients

T2 - An open-label pilot study

AU - Hammack, Julie E.

AU - Mailliard, James A.

AU - Loprinzi, Charles Lawrence

AU - Respond, Raylene M.

AU - O'Fallon, Judith R.

AU - Wilwerding, Mary B.

AU - Reuter, Nicholas F.

AU - Michalak, John C.

AU - Fidler, Pat

AU - Miser, Angela W.

PY - 1996/10

Y1 - 1996/10

N2 - We performed an open label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our 7-day study included 35 patients all of whom had failed a trial of an opioid analgesic conventionally used for moderate pain. Patients received either a 25 μg/hr or 50 μg/hr fentanyl transdermal patch depending on prior opioid dose. Pain was measured daily utilizing visual analogue (VAS) and categorical (CAT) scales. Hours of nighttime sleep, quality of life, toxicities, and use of rescue medication were also assessed. There was a 24%-29% reduction in mean VAS and CAT pain scores as compared with the baseline and a 25% increase in mean hours of nighttime sleep. Fifty-nine percent of those patients responding (46% of all study patients) were satisfied to very satisfied with the analgesia provided by transdermal fentanyl. Six percent of all study patients were not at all satisfied with the pain relief obtained. Toxicities were similar to those seen with other opioids. No patient developed severe sedation or respiratory depression. The 25-50 μg/hr patch appears to be a safe starting dosage in ambulatory patients previously receiving opioids conventionally used for moderate pain.

AB - We performed an open label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our 7-day study included 35 patients all of whom had failed a trial of an opioid analgesic conventionally used for moderate pain. Patients received either a 25 μg/hr or 50 μg/hr fentanyl transdermal patch depending on prior opioid dose. Pain was measured daily utilizing visual analogue (VAS) and categorical (CAT) scales. Hours of nighttime sleep, quality of life, toxicities, and use of rescue medication were also assessed. There was a 24%-29% reduction in mean VAS and CAT pain scores as compared with the baseline and a 25% increase in mean hours of nighttime sleep. Fifty-nine percent of those patients responding (46% of all study patients) were satisfied to very satisfied with the analgesia provided by transdermal fentanyl. Six percent of all study patients were not at all satisfied with the pain relief obtained. Toxicities were similar to those seen with other opioids. No patient developed severe sedation or respiratory depression. The 25-50 μg/hr patch appears to be a safe starting dosage in ambulatory patients previously receiving opioids conventionally used for moderate pain.

KW - cancer pain

KW - opioids

KW - Transdermal fentanyl

UR - http://www.scopus.com/inward/record.url?scp=0030271489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030271489&partnerID=8YFLogxK

U2 - 10.1016/0885-3924(96)00191-1

DO - 10.1016/0885-3924(96)00191-1

M3 - Article

C2 - 8898507

AN - SCOPUS:0030271489

VL - 12

SP - 234

EP - 240

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 4

ER -